EP Patent

EP3072504A1 — Small-volume oral transmucosal dosage forms

Assigned to Talphera Inc · Expires 2016-09-28 · 10y expired

What this patent protects

Small-volume oral transmucosal dosage forms or NanoTabs ® comprising a predetermined amount of a pharmaceutically active drug are provided. Exemplary applications include use of the NanoTabs ® to administer a drug for the treatment of acute, post-operative or breakthrough pain.

USPTO Abstract

Small-volume oral transmucosal dosage forms or NanoTabs ® comprising a predetermined amount of a pharmaceutically active drug are provided. Exemplary applications include use of the NanoTabs ® to administer a drug for the treatment of acute, post-operative or breakthrough pain.

Drugs covered by this patent

sufentanil-citrate (SUFENTANIL CITRATE)

Patent Metadata

Patent number: EP3072504A1
Jurisdiction: EP
Classification: —
Expires: 2016-09-28
Drug substance claim: No
Drug product claim: No
Assignee: Talphera Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.